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Introduction 
This paper accompanies the report Medical use of cannabis and cannabinoids — 
questions and answers for policymaking and summarises the findings of major 
systematic reviews of the evidence on the effectiveness and safety of cannabis and 
cannabinoids when used to treat symptoms of various medical conditions. It provides 
more detail on topics summarised in the main report, in particular on the sections on 
the available evidence on the effectiveness of medical use of cannabis and 
cannabinoids and those on the health risks and potential unintended consequences 
associated with the medical use of cannabis and cannabinoids. 
The first section of this paper summarises in detail the conclusions of three influential 
peer-reviewed publications (Koppel et al., 2014; NASEM, 2017; Whiting et al., 2015). 
These reviews evaluated all the published evidence on the efficacy and safety of 
cannabis for multiple medical uses. They used a clearly specified search strategy to 
identify studies, clear rules for deciding which studies to include and exclude, 
standardised criteria for evaluating the degree of bias in the studies and explicit 
criteria for synthesising the overall evidence. 
The paper then summarises the findings of systematic reviews and meta-analyses of 
the evidence on the effectiveness of cannabinoids in treating chronic pain; 
chemotherapy induced nausea and vomiting in cancer patients; appetite stimulation 
in HIV/AIDS; intractable epilepsy; and palliative care for cancer. All these reviews 
used explicit search criteria, standardised tools for assessing study bias and explicit 
methods of synthesising the overall findings. Their degree of agreement is also 
summarised in a table. 
A third section summarises reviews of the adverse effects of medical use of 
cannabis as indicated in randomised controlled clinical trials. The section includes 
the results of a meta-analysis of adverse effects reported in clinical trials conducted 
by Whiting et al. (2015). The section also considers long-term harms reported among 
recreational cannabis users that may be potential adverse effects of long-term 
medical use of cannabis and cannabinoids. 
Finally, the paper includes an overview of studies, primarily conducted in the US, 
that explore the potential unintended consequences of the medical use of cannabis 
and cannabinoids. 
Cannabis and cannabinoids have been made available in a wide range of forms, and 
the various products and preparations tended to be described in different ways in 
different publications. While the main report uses a new typology in describing the 
different forms in which cannabis and cannabinoids are made available, we have 
chosen in the background paper to use the original terminology from the studies 
under consideration. 
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1. Reviews of the evidence on the efficacy and safety of
cannabis and cannabinoids for multiple disorders — three key
evidence reviews
Koppel, B. S., et al. (2014) 
Koppel, B. S., Brust, J. C., Fife, T., Bronstein, J., Youssof, S., Gronseth, G. and 
Gloss, D. (2014), ‘Systematic review: efficacy and safety of medical marijuana in 
selected neurologic disorders: report of the Guideline Development Subcommittee of 
the American Academy of Neurology’, Neurology 82, pp. 1556-1563. 
These authors reviewed evidence on the safety and efficacy of cannabinoids in 
relieving or reducing spasticity in patients with multiple sclerosis (MS); central pain 
and painful spasms in MS; bladder dysfunction in MS; involuntary movements in MS; 
movement disorders in Huntington’s disease and dyskinesia in Parkinson’s disease; 
and seizure in epilepsy. 
They conducted a systematic search up to November 2013 and included 33 clinical 
trials in their analysis. Clinical trials were classified into four categories defined by 
the American Academy of Neurology. Class I studies provided the strongest 
evidence, being double-blind randomised controlled trials (RCTs) in representative 
patients with similar symptom severity at baseline and the outcomes of which were 
assessed on objective measures. The remaining study classes provided weaker 
evidence because they lacked one or more of these desirable characteristics. For 
each symptom, the authors summarise the overall evidence in terms of the number 
of studies in classes I to IV, describe each study in detail and draw overall 
conclusions about the evidence. Only their conclusions are summarised below, 
along with any comments on the clinical context in which the cannabinoids might be 
used. 
Spasticity in MS 
This was the most extensively investigated symptom, with 4 class I, 4 class II and 9 
class III studies. Koppel et al. summarised the results for each type of cannabinoid 
studied, that is, nabiximols; oral cannabis extract (OCE) and tetrahydrocannabinol 
(THC); oral cannabinoids; and ‘smoked marijuana’. They concluded that OCE, THC 
and nabiximols are each ‘probably effective’ in reducing self-reported spasticity in the 
short term but ‘probably ineffective’ in reducing objective measures of spasticity. The 
effectiveness of smoked marijuana was ‘uncertain’. They noted that the 
cannabinoids were used in addition to standard therapy, so no conclusion could be 
drawn on the comparative effectiveness of cannabinoids and standard treatments for 
spasticity. The outcomes were better when assessed by patient ratings of 
improvement. The authors suggested this might be because the cannabinoids 
improved mood or provided pain relief that allowed patients to move more freely. 
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Central pain in MS 
This was the next most studied symptom, with 5 class I, 2 class II and 6 class III 
studies. The authors concluded that OCE was effective and that THC and nabiximols 
were ‘probably effective’ in reducing central pain. The efficacy of smoked marijuana 
was uncertain because there were too few studies. 
Bladder dysfunction in MS 
This symptom was assessed in a minority of the studies of cannabinoids in MS. The 
authors concluded that nabiximols was ‘probably effective’ in reducing the number of 
bladder voids per day at 10 weeks and that THC and OCE were ‘probably 
ineffective’. Nabiximols was judged to be of uncertain effectiveness in reducing 
overall bladder symptoms because there were contradictory results from two class I 
trials that measured this outcome. 
Tremor in MS 
Tremor as a secondary symptom was assessed in six studies of cannabinoids in 
patients with MS. The authors concluded that THC and OCE were ‘probably 
ineffective’ and nabiximols was ‘possibly ineffective’ in reducing tremor in MS. 
Involuntary movement disorders 
There were very few studies of the effects of cannabinoids in Huntington’s disease 
and the few that were available were underpowered to detect effects. Accordingly, 
no reliable conclusions could be drawn on the effectiveness of cannabinoids in this 
disease. The authors concluded that OCE was ineffective in reducing dyskinesia in 
Parkinson’s disease. They found that there were insufficient data to assess the 
efficacy of cannabinoids in reducing symptoms of Tourette syndrome or cervical 
dystonia. 
Epilepsy 
There were no RCTs for review and only two low-quality studies that failed to detect 
any benefit of cannabinoids in reducing the frequency of seizures. The authors 
concluded that these studies provided insufficient evidence to assess the 
effectiveness of cannabinoids in epilepsy. 
Adverse effects 
The authors reviewed data on adverse events in studies of cannabinoid use for less 
than 6 months in 1 619 patients. They found that 6.9 % of patients in the cannabinoid 
groups withdrew from treatment because of adverse events compared with 2.2 % in 
the placebo groups. The adverse symptoms reported in at least two studies were 
nausea, weakness, behavioural or mood changes, suicidal ideation, hallucinations 
and dizziness. 
Among these adverse events, the authors identified cognitive impairment as a 
concern with regard to the use of cannabinoids in patients with MS because many 
had cognitive impairment caused by their disease. They also expressed concern 
about the possibility that cannabinoids might increase suicidal ideation in MS 
patients who were at increased risk of suicide. 
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Recommendations for future research 
The findings of the Koppel et al. review are summarised in Table 1. In discussing 
future research, Koppel et al. noted that a probable placebo effect from psychoactive 
cannabinoids complicated assessment of their therapeutic effects. They also 
acknowledged the major disincentives to doing clinical research on cannabinoids, 
namely regulatory requirements, a prohibition on patients driving and the need to rely 
on subjective assessment of patient outcomes. They nonetheless argued that we 
needed larger, better-designed RCTs to properly assess the efficacy of 
cannabinoids. They found the current literature hard to summarise because multiple 
cannabis products were used in varying doses, studies were often underpowered to 
detect effects and they often had high rates of patient dropout.  
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Table 1: Summary table, Koppel et al., 2014 
 
 
Whiting, P. F., et al. (2015) 
 
Whiting, P. F. Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., 
et al. (2015), ‘Cannabinoids for medical use: a systematic review and meta-analysis’, 
JAMA 313, pp. 2456-2473. 
Whiting et al. (2015) conducted a systematic review of randomised controlled clinical 
trials of cannabinoids for various medical uses. They conducted meta-analyses when 
there were two or more RCTs that compared cannabis or a cannabinoid with another 
treatment such as usual care, placebo or no treatment. The review was 
commissioned by the Swiss Federal Office of Public Health and published in JAMA. 
The authors evaluated evidence on the safety and efficacy of cannabinoids in 
treating the following disorders: 
• nausea and vomiting in patients undergoing chemotherapy for cancer 
• appetite stimulation in HIV/AIDS patients 
• chronic pain 
• spasticity due to MS or paraplegia 
• depression 
Symptoms 
studied 
Conclusions reached  
Symptoms of MS  
Muscle spasticity  Nabiximols probably effective in reducing subjective symptoms 
Central pain  Nabiximols probably effective in reducing central pain 
Bladder 
dysfunction 
Nabiximols probably effective in reducing frequency of voiding; 
their effects on other bladder symptoms were uncertain 
Tremor Nabiximols probably ineffective in reducing tremor 
 
Movement 
disorders 
 
Huntington’s 
disease  
Insufficient evidence to draw reliable conclusions  
Parkinson’s 
disease 
Cannabinoids probably ineffective in treating dyskinesia 
Tourette syndrome Insufficient evidence to draw reliable conclusions 
Cervical dystonia Insufficient evidence to draw reliable conclusions 
 
Epilepsy Insufficient evidence to assess the effectiveness of cannabidiol 
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• anxiety disorder 
• sleep disorder 
• psychosis 
• intraocular pressure in glaucoma 
• Tourette syndrome 
The authors searched electronic databases of scientific studies in all languages and 
identified RCTs. They used the Cochrane Collaboration tool to assess the risk of 
bias in each of the studies. They classified studies as having a high risk of bias if 
there was a high risk of bias in at least one domain (e.g. sampling, design, missing 
data, patients’ awareness of treatment) and as having a low risk of bias if there was 
no risk of bias in any of these domains. They conducted meta-analyses if there were 
two or more RCTs for a specific health outcome with one or more cannabinoids. 
They also conducted a meta-analysis of adverse events reported for all cannabinoids 
in clinical trials for all conditions reviewed. 
In Whiting et al.’s review, 79 studies met the criteria for inclusion. They screened 505 
studies that were potentially relevant from 23 754 papers identified in their initial 
searches. These studies included 34 parallel group studies (with 4 436 patients) and 
45 crossover trials (with 2 026 patients). 
Only 5 of the trials were rated as having a low risk of bias; 55 were rated as having a 
high risk of bias. In the remainder, the degree of bias was unclear because of poor 
reporting of trial methods. The major sources of bias were incomplete outcome data 
(in more than half of the studies), uncertainty about whether patients were blind as to 
the treatment they received (57 %) and selective reporting of study outcomes (16 %). 
Nausea and vomiting 
Whiting et al. analysed data from 28 studies involving 1 772 patients that assessed 
the effectiveness of cannabinoids in treating nausea and vomiting related to 
chemotherapy for cancer. These included 14 trials of nabilone, 3 of dronabinol, 1 of 
nabiximols, 4 of levonantradol and 6 of THC. All trials included a placebo. Some 
trials also included an active treatment comparison, most often the anti-emetic drug 
prochlorperazine (15 studies). 
The risk of basis was rated as high in 23 out of 28 studies and unclear in the 
remainder. A meta-analysis of all these studies showed that cannabinoids achieved 
more complete control of nausea than placebo (odds ratio (OR) = 3.82 (95 % 
confidence interval (CI) 1.65 to 9.42)). 
Appetite stimulation 
This outcome was assessed in only four studies that included 255 patients, primarily 
with AIDS-related wasting. All the studies compared dronabinol with placebo in 
stimulating appetite. All were judged to have a high risk of bias and hence 
considered to provide weak evidence of efficacy. 
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Chronic pain 
Whiting et al. reviewed 28 studies involving 2 454 patients of cannabinoids used to 
treat chronic pain. Seventeen trials were judged to have a high risk of bias. The trials 
evaluated nabiximols (13), THC (4), dronabinol (2), vaporised cannabis (1), ajulemic 
acid (1), oral THC (1) and nabilone (1). Only one study used an active treatment 
comparison (amitriptyline); the remainder looked at efficacy in comparison with a 
placebo. 
The studies involved the following chronic pain conditions: neuropathic pain (12); 
cancer pain (3); diabetic neuropathy (3); fibromyalgia (2) HIV neuropathy (2), 
refractory pain in MS (1), rheumatoid arthritis (1), non-cancer pain (1), central pain 
(1) and musculoskeletal pain (1). 
A meta-analysis indicated that the cannabinoids were superior to placebo in reducing 
pain and that there were no differences in responses for different types of pain or 
different cannabinoids. 
Spasticity due to MS or paraplegia 
A total of 14 studies evaluated the effects of cannabinoids on muscle spasticity: 11 
studies in patients with MS and 3 in patients with paraplegia. They included 2 280 
patients. All were placebo-controlled studies. Seven were judged to have a high risk 
of bias, two were considered to have a low risk of bias and the degree of bias was 
unclear in five studies. 
The cannabinoids evaluated included nabiximols (6 studies), dronabinol (3 studies), 
nabilone (1 study); THC/CBD combinations (4 studies) and smoked THC (1 study). 
A meta-analysis found greater improvements in self-reported spasticity in those 
treated with cannabinoids than in those given a placebo, but there was weak 
evidence of improved clinician ratings of muscle spasticity. 
Depression 
The review did not include any RCTs that evaluated the effects of cannabinoids on 
depression as a primary disorder, but five RCTs of patients treated with 
cannabinoids for other medical conditions assessed depression as a secondary 
endpoint. This included four trials in patients with chronic pain and one trial looking at 
muscle spasticity in MS. Three of the trials were judged to have a high risk of bias. 
The cannabinoids evaluated were dronabinol (1 study), nabiximols (3 studies) and 
nabilone (1 study). No trial found a significantly greater reduction in depression in the 
patients treated with a cannabinoid than in those given a placebo. 
Anxiety 
There was only one small RCT that evaluated the effects of a cannabinoid in treating 
anxiety in general anxiety disorder. It was judged to have a high risk of bias and 
found only a small difference compared with placebo. 
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Sleep disorder 
There were two studies of cannabinoids used to treat sleep disorders. They included 
one parallel group RCT and one crossover study, both of which were judged to have 
a high risk of bias. These studies provided some evidence that cannabinoids 
improved sleep. 
Psychosis 
Two studies were included on the effects of cannabidiol (CBD) on psychotic 
symptoms. These included 71 patients and were judged to have a high risk of bias. 
There were no differences in outcomes between patients given the cannabinoid and 
those given a placebo. 
Intra-ocular pressure in glaucoma 
Only one small crossover study involving six patients was included. It was judged to 
have a high risk of bias and it did not find any difference between the cannabinoid 
and placebo. 
Tourette syndrome 
Two small placebo-controlled studies involving 36 patients reported suggestive 
evidence that there were fewer tics reported by patients receiving the cannabinoid 
than by those receiving the placebo. 
Summary 
Whiting et al. concluded that there was: 
• moderate-quality evidence that cannabinoids were effective in treating 
chronic neuropathic and cancer pain and muscle spasticity in patients with 
MS; 
• low-quality evidence that cannabinoids improved nausea and vomiting in 
cancer patients, increased appetite and weight gain in AIDS patients, 
improved symptoms of sleep disorders and improved symptoms of Tourette 
syndrome; 
• low-quality evidence for the efficacy of cannabinoids in treating anxiety, 
psychosis and depression; 
• an increased risk of adverse events for all cannabinoids; 
• a need for large, robust well-controlled RCTs to confirm that cannabinoids 
were effective in treating most of these clinical outcomes. 
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NASEM (2017) 
 
US National Academies of Sciences, Engineering, and Medicine (NASEM) 
(2017), The health effects of cannabis and cannabinoids: the current state of 
evidence and recommendations for research, National Academies Press, 
Washington, DC. 
A committee of the US National Academy of Sciences (NASEM, 2017) reviewed 
research that had been published since the Academy had last reviewed the medical 
use of cannabis, in 1999. The committee conducted a review of reviews, that is, they 
summarised findings of high-quality systematic reviews and meta-analyses of the 
research literature. They also assessed high-quality research studies not included in 
the systematic reviews or published after the most recent systematic review. If there 
were no systematic reviews, the committee reviewed primary research published 
between January 1999 and August 2016. The committee synthesised the evidence 
using the following levels of confidence in conclusions that cannabis or cannabinoids 
were or were not effective in treating a medical condition (Table 2). 
 
 
Table 2: Criteria that NASEM used for summarising strength of evidence  
Strength of 
conclusion  
RCT evidence on 
efficacy from 
Support from 
other studies 
Role of chance, 
bias and 
confounding 
Conclusive Strong study 
designs 
Many studies; no 
opposing findings 
Can be ruled out 
with reasonable 
confidence 
Substantial Strong study 
designs 
Several studies; 
no opposing 
findings 
Cannot be ruled 
out but minor  
Moderate Some good- to 
fair-quality studies 
Several studies; 
very few or no 
opposing findings 
Cannot be ruled 
out with 
confidence 
Limited Weak study 
designs  
Opposing findings 
from other studies 
Significantly 
uncertain 
Insufficient  No studies or a 
single poor study 
Mixed or no 
findings 
Substantial 
concerns 
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The committee examined evidence on conditions for which medical use of cannabis 
or cannabinoids has been advocated in the US. These included the following groups 
of medical conditions: chronic pain; cancer; nausea and vomiting produced by 
cancer therapy; appetite stimulation in HIV/AIDS, cancer and anorexia nervosa; 
irritable bowel syndrome; epilepsy; spasticity in MS and spinal cord injury; Tourette 
syndrome; amyotrophic lateral sclerosis; Huntington’s disease; Parkinson’s disease; 
dystonia; Alzheimer’s disease; glaucoma; traumatic brain injury and spinal cord 
injury; addiction; anxiety disorders; depressive disorders; sleep disorders; post-
traumatic stress disorder; and schizophrenia. 
The committee reviewed evidence on cannabis that was smoked and inhaled, 
synthetic THC (dronabinol), THC analogues (nabilone), CBD, and medicinal 
cannabis plant extracts that included nabiximols (plant extract with equal ratios of 
THC and CBD) and Epidiolex (a CBD-based plant extract). 
Chronic pain 
The committee found five systematic reviews of fair to good quality. They gave the 
greatest weight to the most comprehensive high-quality review (Whiting et al., 2015). 
Its findings were consistent with those of other reviews (many of which included 
studies with weaker designs, such as crossover studies) in suggesting that 
cannabinoids have a modest effect in reducing some types of pain. 
Whiting et al. identified 28 RCTs that included 2 454 patients with various types of 
chronic pain, who were randomly assigned to receive either cannabis (or a 
cannabinoid) or a comparison treatment. The comparison was placebo in all but one 
trial. Whiting et al. did not find any differences in efficacy between different 
cannabinoids, but the small sample sizes of the studies limited the statistical power 
to detect differences. 
Two RCTs had been published since the Whiting et al. review. These compared the 
effects of varying doses of inhaled cannabis flower and placebo on acute pain. One 
found that inhaled cannabis produced a dose-related reduction in pain (Wallace et 
al., 2015); the other did not (Wilsey et al., 2016). 
The committee concluded that there was ‘substantial evidence that cannabis is an 
effective treatment for chronic pain in adults’. It noted that most trials evaluated 
nabiximols in treating neuropathic pain in MS. Less was known about the 
effectiveness and side effects of cannabis products sold in US medical cannabis 
dispensaries, such as vaporised cannabis flower, concentrates and edible forms of 
cannabis. 
Nausea and vomiting in patients undergoing chemotherapy for cancer 
The committee relied on the review of Whiting et al. (2015) and a Cochrane 
Collaboration review by Smith et al. (2015). Whiting et al. (2015) summarised 28 
RCTs comparing various cannabinoids with placebo or an anti-emetic drug (most 
often prochlorperazine). In most of these trials, cannabinoids produced greater 
reductions in nausea than a placebo and they provided control as good as and 
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sometimes better than that provided by the anti-emetic drug with which they were 
compared. 
The Cochrane review included 23 clinical trials, 19 of which were crossover studies. 
Smith et al. (2015) concluded that cannabinoids were more effective than placebo 
and similar in effectiveness to conventional anti-emetics. They also found that 
cannabinoids caused more adverse events, such as dizziness, dysphoria, euphoria, 
‘feeling high’ and sedation. They found a weak patient preference for cannabinoids 
over placebo and a stronger preference for cannabinoids over other anti-emetics. 
They concluded that cannabinoids should be used only when other anti-emetics had 
failed. 
The committee identified one additional study, conducted in 2007, that had not been 
included in either of these reviews. It compared the anti-emetic effects of dronabinol 
with those of ondansetron and found the two drugs to be equally effective (Meiri et 
al., 2007). The committee concluded that there was ‘conclusive evidence that oral 
cannabinoids are effective anti-emetics in the treatment of chemotherapy-induced 
nausea and vomiting’ (pp. 4-7). 
Anorexia and weight loss in HIV/AIDS, cancer and anorexia nervosa 
The committee relied on two systematic reviews. Whiting et al. (2015) reviewed four 
RCTs of cannabinoids as appetite stimulants in 255 patients with HIV/AIDS. All were 
judged to have a high risk of bias. Lutge et al. (2013) reviewed seven clinical trials 
and concluded that there was a lack of evidence for the efficacy and safety of 
cannabis and cannabinoids in AIDS-related anorexia. No additional studies were 
identified because the syndrome had disappeared ‘since effective antiretroviral 
therapies became available in the mid-1990s’ (NASEM, 2017, pp. 4-8). 
There were no systematic reviews of controlled trials of cannabis or cannabinoids in 
cancer-related anorexia. Two controlled studies were reviewed. The first was 
discontinued because of high patient attrition due to side effects and a lack of 
efficacy (Strasser et al., 2006). Another larger trial found that megestrol acetate was 
better than dronabinol in stimulating appetite in cancer patients (Jatoi et al., 2002). 
There were no systematic reviews and only a small number of small-sample trials of 
cannabinoids in anorexia nervosa (Andries, 2014). 
The committee concluded that there was (1) ‘limited evidence that cannabis and oral 
cannabinoids are effective in increasing appetite and decreasing weight loss 
associated with HIV/AIDS’ and (2) ‘insufficient evidence to support or refute the 
conclusion that cannabinoids are an effective treatment for cancer-associated 
anorexia-cachexia syndrome and anorexia nervosa’ (pp. 4-10). 
Epilepsy 
The committee found two fair-quality reviews of cannabis and cannabinoids as single 
or added treatments for epilepsy (Gloss and Vickrey, 2014; Koppel et al., 2014). 
These summarised a small number of poor-quality studies in 48 patients. No 
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additional RCTs or other studies had been published, but several clinical trials had 
been completed without reporting their results at the time of the review. 
One open-label study of oral CBD had been published since the Whiting et al. and 
NASEM reviews (Devinsky et al., 2016; Rosenberg, 2015). It examined the efficacy 
of oral CBD in reducing seizures in 162 children with intractable epilepsy and found a 
37 % reduction in the frequency of seizures. A case series was reported from Israel 
(Tzadok et al., 2016). Neither of these was a double-blind study and there were no 
comparison groups. 
The committee assessed the evidence on epilepsy as highly subject to bias because 
neither doctors nor patients were blind to treatment and in the absence of a 
comparison group it was difficult to be sure that the apparent benefits of CBD were 
not due to placebo effects or regression to the mean. The committee concluded that 
there was ‘insufficient evidence to support or refute the conclusion that cannabinoids 
are effective in the treatment of epilepsy’ (pp. 4-13). 
Spasticity 
The committee relied on Whiting et al.’s 2015 review of 11 parallel group studies of 
nabilone and nabiximols in patients with MS and three studies of cannabinoids in 
patients with paraplegia. A meta-analysis of three studies of nabiximols in MS found 
reasonably consistent evidence of clinical improvement in patient-rated symptoms of 
spasticity. There was no difference between cannabinoids and placebo when 
spasticity was rated by physicians. Koppel et al. (2014) concluded after reviewing 14 
studies in MS that oral cannabinoids and nabiximols was ‘probably effective in 
reducing severity of patient-rated spasticity but not physician-rated symptoms’. 
The committee concluded that nabiximols and cannabinoids were ‘probably effective’ 
in reducing the patient-rated severity of spasticity in MS but found that there was 
insufficient evidence to judge their efficacy in treating spasticity in people with spinal 
cord injuries (pp. 4-15). 
Sleep disorders 
Whiting et al. (2015) reviewed evidence from two RCTs with 54 participants who 
received nabilone and dronabinol for sleep problems. A trial with a high risk of bias in 
22 patients with obstructive sleep apnoea showed greater benefits from dronabinol 
than placebo. A crossover trial with a low risk of bias in 32 patients with fibromyalgia 
found that nabilone resulted in greater reductions in insomnia than amitriptyline. 
Nineteen trials of 3 231 participants with chronic pain or MS reported sleep 
outcomes. In these trials, nabiximols (13 studies), THC/CBD capsules (2 studies), 
smoked THC (2 studies), and dronabinol or nabilone were compared with placebo. 
Eleven of nineteen trials had a high risk of bias, six had an uncertain risk of bias and 
two had a low risk of bias. A meta-analysis found that cannabinoids produced 
greater improvements than placebo in sleep quality in eight trials and less sleep 
disturbance in three trials. There were small improvements on a 10-point scale. 
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The committee concluded that there was moderate evidence that cannabinoids, 
primarily nabiximols, are effective in improving short-term sleep outcomes in 
individuals with obstructive sleep apnoea syndrome. 
 
Conditions for which there was insufficient or limited evidence 
The committee concluded that there was limited evidence of effectiveness for the 
following: 
• behavioural disturbance in dementia 
• glaucoma 
• cannabis use disorders 
• spinal cord injury and intracranial haemorrhage 
• anxiety symptoms 
• depression 
• post-traumatic stress disorder 
• schizophrenia and other psychoses. 
 
The committee concluded that there was insufficient evidence to evaluate the 
effectiveness of cannabinoids in treating the following conditions: 
 
• brain cancer, glioma 
• irritable bowel syndrome 
• Tourette syndrome 
• amyotrophic lateral sclerosis 
• Huntington’s disease 
• Parkinson’s disease 
• dystonia. 
Summary of the committee’s conclusions 
The committee summarised its conclusions on medical use of cannabinoids as 
follows: 
 
• In adults with chemotherapy-induced nausea and vomiting, oral cannabinoids 
are effective antiemetics. 
• In adults with chronic pain, patients who were treated with cannabis or 
cannabinoids are more likely to experience a clinically significant reduction in 
pain symptoms. 
• In adults with multiple sclerosis (MS)-related spasticity, short-term use of oral 
cannabinoids improves patient-reported spasticity symptoms. 
• For these conditions the effects of cannabinoids are modest; for all other 
conditions evaluated there is inadequate information to assess their effects. 
 
The findings of the Whiting et al. and NASEM reviews are shown for comparison in 
Table 3.   
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Table 3: Comparison of conclusions in the Whiting et al. and NASEM reviews 
Symptom or disorder Whiting et al., 2015 NASEM, 2017 
Nausea and vomiting Low-quality evidence that 
THC is superior to 
placebo in reducing 
symptoms 
Conclusive evidence that 
oral cannabinoids are 
effective in the treatment 
of chemotherapy-induced 
nausea and vomiting 
Appetite stimulation Low-quality evidence that 
THC increases appetite in 
AIDS 
Limited evidence that 
cannabinoids are effective 
in increasing appetite and 
decreasing weight loss in 
HIV/AIDS 
Chronic pain Moderate-quality 
evidence that 
cannabinoids are superior 
to placebo in reducing 
chronic pain and cancer 
pain 
Substantial evidence that 
cannabis is effective for 
chronic pain, especially 
neuropathic pain in MS 
Muscle spasticity Moderate-quality 
evidence that nabiximols 
is superior to placebo in 
reducing subjective 
symptoms in MS; weak 
evidence for clinician-
rated symptoms 
Cannabinoids are 
probably effective in 
reducing patient-rated 
spasticity in MS; 
insufficient evidence to 
assess efficacy in spinal 
cord injuries 
Epilepsy Not assessed because no 
RCTs 
Insufficient evidence to 
assess effectiveness 
Sleep  Low-quality evidence that 
cannabinoids improve 
sleep  
Nabiximols is effective in 
improving short-term 
sleep outcomes in 
obstructive sleep apnoea 
Depression No evidence that 
cannabinoids are superior 
to placebo  
Limited evidence of 
effectiveness 
Anxiety Insufficient evidence to 
assess effectiveness 
Limited evidence of 
effectiveness 
Psychosis Insufficient evidence to 
assess effectiveness 
Limited evidence of 
effectiveness 
Glaucoma  Insufficient evidence to 
assess effectiveness 
Limited evidence of 
effectiveness 
Tourette syndrome Low-quality evidence that 
cannabinoids improved 
symptoms  
Insufficient evidence to 
assess effectiveness 
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2. Reviews of the evidence on the efficacy and safety of 
cannabis and cannabinoids for specific disorders 
 
Chronic pain 
Andreae, M., Carter, G. M., Shaparin, N., Suslov, K., Ellis, R. J., Ware, M. A. et al., 
(2015), ‘Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual 
patient data’, Journal of Pain 16, pp. 1221-1232. 
Andreae et al. (2015) reported a Bayesian meta-analysis using data from 178 
patients who participated in five RCTs of inhaled vaporised herbal cannabis and 
were assessed for up to 2 weeks. This included two studies of patients with AIDS-
related neuropathy and three studies of patients with various types of neuropathic 
pain caused by, for example, spinal cord injury, diabetes and trauma. All the trials 
used inhaled herbal cannabis that was supplied by the US National Institute on Drug 
Abuse. Participants were generally not blind to the treatment that they received. 
The conclusion of this review was more positive than those of the systematic reviews 
of larger numbers of studies of cannabinoids reviewed below. The odds ratio for a 
30 % reduction in pain was 3.2 and it was estimated that 1 in every 5 or 6 patients 
benefited from the treatment, an effect that the authors argued was comparable to 
that of gabapentin. They acknowledged that the sample sizes in these trials were 
small and recommended larger, pragmatic and longer term clinical studies to see 
whether these good short-term effects were sustained for longer than the 2 weeks 
observed in these studies. 
 
Nugent, S. M., Morasco, B. J., O’Neil, M. E., Freeman, M., Low, A., Kondo, K. et al. 
(2017), ‘The effects of cannabis among adults with chronic pain and an overview of 
general harms: a systematic review’, Annals of Internal Medicine 167, pp. 319-331. 
Nugent et al. (2017) reviewed only controlled clinical trials of the effectiveness of 
plant-based cannabis medicines. These included nabiximols, herbal cannabis and 
cannabis-based oils. They argued that controlled trials of synthetic cannabinoids had 
been reviewed by other groups. Their review included the findings of 13 systematic 
reviews of the evidence from 62 primary studies and their review of evidence from 22 
RCTs included in recent reviews and 8 studies published since these reviews, as 
well as 3 cohort studies of patients with chronic pain. 
Thirteen of the trials examined cannabinoids in chronic neuropathic pain. Eleven 
trials were described as having a low risk of bias, in one trial the risk of bias was 
unclear and there was a high risk of bias in the other. The authors found a very small 
difference in the mean change on a visual analogue scale for pain (VAS) between 
cannabinoids and placebo; the difference was judged to be of limited clinical 
significance. Only a small proportion of patients achieved a 30 % or greater 
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reduction in pain. A 1-year prospective study of patients treated with nabiximols 
found a very small reduction in VAS rating that was not clinically significant. 
Nugent et al. also analysed nine trials of neuropathic pain in MS. Three were rated 
as having a low risk of bias, five were rated as having an unclear risk of bias and one 
was rated as having a high risk of bias. They concluded that there was ‘insufficient 
evidence to characterise the effects of cannabis on pain in patients with MS’ (p. 321), 
largely because of the small number of rigorous studies, the lack of evidence on 
long-term patient outcomes and the small numbers of patients include in the trials. 
They also considered three trials of cannabinoids for treating cancer pain that 
involved 547 patients. Two of these studies had an unclear risk of bias and one had 
a high risk of bias. They concluded that these studies provided ‘insufficient evidence’ 
because of the small number of studies and high patient attrition rate. 
They also reviewed adverse events reported in these trials. They described most of 
the effects as minor and did not find the rate of adverse events significantly different 
between cannabinoids and placebo used to treat chronic pain. Their overall 
conclusion was that there was ‘limited evidence on the potential benefits and harms 
of cannabis use in chronic pain populations’ (p. 325) and only low-quality evidence 
that nabiximols reduced neuropathic pain. 
 
Meng, H., Johnston, B., Englesakis, M., Moulin, D. E. and Bhatia, A. (2017), 
‘Selective cannabinoids for chronic neuropathic pain: a systematic review and meta-
analysis’, Anesthesia and Analgesia 125, pp. 1638-1652. 
Meng et al. (2017) conducted a systematic review and meta-analysis of 11 RCTs 
that evaluated cannabinoids as treatments for chronic neuropathic pain (NP). These 
included studies of dronabinol (1 trial), nabilone (3 trials) and nabiximols (7 trials). In 
all trials, the cannabinoids were adjunctive treatments, that is, they were added to 
other analgesics. The trials include 1 219 patients (614 receiving a cannabinoid and 
605 receiving a comparison treatment (placebo in 10 out of 11 trials). The authors 
used Cochrane Collaboration criteria to rate the degree of study bias and the 
GRADE (Gradings of Recommendation Assessment, Development and Evaluation) 
system to synthesise the evidence. The primary outcome was a change in a 
numerical rating scale of pain that was used in all but one of the trials. Secondary 
outcomes included quality of life, sleep and physical activity. Patients in the trials 
suffered from either central neuropathic pain, for example as a consequence of MS 
or brachial plexus avulsion, or peripheral neuropathic pain due to diabetes or other 
causes. 
Meng et al. assessed the overall risk of bias as low in 10 out of 11 trials. One trial 
had a high risk because it was unclear how patients had been randomised or if 
patients and assessors had been blind as to treatment. Six of the eleven trials found 
that the cannabinoid was superior to placebo, but the mean difference in pain ratings 
between the two was only 0.65 on an 11-point scale. The authors examined 
20 
 
differences in efficacy between different cannabinoids and different types of 
neuropathic pain, but these comparisons were limited by the small number of trials 
and the small sample sizes in the trials. There was suggestive evidence that 
nabiximols was superior to nabilone. In five of the eight studies that assessed quality 
of life and sleep, the cannabinoids were superior to placebo. 
Adverse events were more commonly reported in the cannabinoid group, but these 
were mostly mild to moderate, and the most common involved dizziness, 
somnolence and dry mouth. The severity of adverse events decreased with use, 
suggesting that tolerance developed. There were two severe events reported: 
agitation and paranoid ideation. 
The reviewers’ recommendation was that ‘cannabinoids can be recommended in 
patients with NP syndromes (GRADE: weak recommendation; moderate-quality 
evidence)’ (p. 1648). They described the mean difference in numerical rating scale 
pain scores (on a10-point scale) between patients receiving cannabinoids and those 
receiving a placebo as ‘significant but clinically small’ (p. 1648). They recommended 
larger RCTs comparing different cannabinoids (THC, varying combinations of THC 
and CBD) in their effects on chronic neuropathic pain. 
 
Mucke, M., Phillips, T., Radbruch, L., Petzke, F. and Hauser, W. (2018a), ‘Cannabis-
based medicines for chronic neuropathic pain in adults’, Cochrane Database of 
Systematic Reviews 3, CD012182. 
Mucke et al. (2018a) assessed studies that compared the efficacy of cannabis-based 
medicines (herbal, plant-based and synthetic) with placebo in chronic neuropathic 
pain in adults. They restricted their search to randomised double-blind controlled 
trials with minimum treatment duration of at least 2 weeks and a minimum of 10 
participants per treatment arm. 
The outcomes that they assessed were the proportion of patients who achieved 
50 % and 30 % reductions in pain and the number who needed to be treated to 
benefit. They included 16 studies with 1 750 participants who received a cannabis-
based medicine or placebo for 2 to 26 weeks. The cannabinoids studied included 
nabiximols (10 studies), nabilone (2 studies), herbal cannabis (2 studies) and 
dronabinol (2 studies). The comparison treatment was placebo in 15 studies and 
dihydrocodeine in 1 study. The authors rated the study quality as low in 2 studies, 
moderate in 12 studies and high in 2 studies. Nine studies were assessed as having 
a high risk of bias because of small sample sizes. 
Mucke et al. found that the percentage of patients who achieved a 50 % reduction in 
pain when treated with cannabinoids was 21 %, compared with 17 % for placebo. 
The number who needed to be treated to benefit was 20. There was weaker 
evidence of benefit on secondary outcomes that included the Patient Global 
Impression of Change scale (26 % vs. 21 %) and the percentage who achieved a 
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30 % reduction in pain (39 % vs. 33 %), for which the number who needed to be 
treated to benefit was 11. They found more withdrawals from treatment because of 
adverse events in the cannabinoid condition than in the placebo condition (10 % vs. 
5 %). 
The authors concluded that the potential benefits of cannabinoids in treating chronic 
neuropathic pain might be outweighed by the harms. They found the quality of 
evidence poor because most studies excluded patients with a history of substance 
abuse and used small samples. Their ‘bottom line’ was that ‘there is a lack of good 
evidence that any cannabis-derived product works for any chronic neuropathic pain’. 
 
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R. et al. 
(2018a), ‘Cannabis and cannabinoids for the treatment of people with chronic non-
cancer pain conditions: a systematic review and meta-analysis of controlled and 
observational studies’, Pain 159, pp. 1932-1954. 
Stockings et al. (2018a) examined evidence from controlled clinical trials and 
observational studies on the efficacy of cannabinoids in treating chronic non-cancer 
pain (CNCP). They also considered differences in outcomes between different types 
of cannabinoid in treating specific CNCP conditions. They included RCTs and non-
RCTs and used the IMMPACT guidelines to assess the clinical significance of CNCP 
outcomes (IMMPACT: Initiative on Methods, Measurement, and Pain Assessment in 
Clinical Trials). 
Their review included 91 publications that reported 104 studies. These included 
9 958 participants in 47 RCTs (24 parallel group studies and 23 crossover trials) and 
57 observational studies that did not involve random assignment to treatment. 
Of the studies, 48 were of patients with neuropathic pain (16 in patients with MS and 
32 in patients with neuropathic pain other than MS-related). They also included 7 
studies of patients with fibromyalgia, 1 study of patients with rheumatoid arthritis and 
48 studies of other types of CNCP (13 of MS-related pain, 6 of visceral pain and 29 
of mixed or undefined CNCP). 
The percentage of CNCP patients who achieved a 30 % reduction in pain intensity 
when averaged across RCTs was 29 % for patients treated with cannabinoids versus 
26 % in those who received a placebo. This difference was statistically significant. 
The number of patients who needed to be treated to benefit was 24 when a 50 % 
reduction in pain was used as the outcome. The proportion achieving this level of 
pain reduction was 18 % in those who received a cannabinoid and 14 % in those 
who received a placebo. This difference was not statistically significant. The overall 
change in pain intensity was equivalent to a 3 mm greater reduction on a 100 mm 
visual analogue scale in those treated with a cannabinoid than in those given a 
placebo. 
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In the RCTs, the proportion of patients reporting any adverse event was 81 % in 
those who received a cannabinoid compared with 66 % in those who received a 
placebo. The number of patients who needed to be treated to harm was six. There 
were no significant effects of cannabinoids on physical or emotional functioning, and 
there was only low-quality evidence that cannabinoids improved sleep or patients’ 
global impression of change. 
Stockings et al. concluded that the evidence for the effectiveness of cannabinoids in 
treating CNCP was limited. The number of patients who needed to be treated to 
benefit was high, while the number who needed to be treated to harm was low. 
There was limited evidence of benefit in other pain-related domains. The authors’ 
summary was that it was ‘unlikely that cannabinoids are highly effective medicines 
for CNCP’. 
 
Chemotherapy-induced nausea and vomiting in cancer patients 
Smith, L., Azariah, F., Lavender, V. T., Stoner, N. S. and Bettiol, S. (2015), 
‘Cannabinoids for nausea and vomiting in adults with cancer receiving 
chemotherapy’, Cochrane Database of Systematic Reviews 11, CD009464. 
Smith et al. (2015) reviewed 23 RCTs that compared the effectiveness of a 
cannabinoid (most often dronabinol) with either placebo or an active treatment for 
nausea and vomiting in cancer patients who were undergoing chemotherapy. Most 
of the studies were crossover trials and the majority were assessed as having a high 
risk of bias because of a lack of clarity about how patients were allocated to 
treatment, a lack of participant blindness to treatment or high rates of subject 
attrition. The trials were conducted between 1975 and 1991, so none could compare 
cannabinoids with the more effective anti-emetic drugs developed since that time. 
Complete control of vomiting was assessed in three trials with 168 participants. The 
cannabinoid was found to completely control vomiting in a larger proportion of 
patients than placebo, but these studies were described as of low quality. The 
outcome of complete control of nausea and vomiting was assessed in two trials with 
288 participants and cannabinoids were found to be superior to placebo. Patients 
who received the cannabinoid were more likely to withdraw from treatment because 
of adverse events than those who received the placebo, but this effect was not 
statistically significant. 
An analysis of trials that compared cannabinoids with other anti-emetics did not find 
any difference between the cannabinoid and prochlorperazine on any measure of 
control of nausea and vomiting. The sample sizes in these studies were small, 
however, so the statistical power of these comparisons was low. Patients who 
received a cannabinoid were more likely to withdraw because of adverse events than 
those taking prochlorperazine. 
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The overall quality of the evidence was low because most studies had a moderate 
risk of bias and they did not reflect current chemotherapy and anti-emetic regimens. 
The evidence was graded as low for the majority of outcomes, indicating that the 
reviewers were not very confident of the results. They also believed that research on 
cannabinoids in newer chemotherapy regimens and in comparison with newer anti-
emetic drugs could modify the conclusions. 
 
Studies of appetite stimulation in HIV/AIDS 
Lutge, E., Gray, A. and Siegfried, N. (2013), ‘The medical use of cannabis for 
reducing morbidity and mortality in patients with HIV/AIDS’, Cochrane Database of 
Systematic Reviews 4, CD005175. 
Lutge et al. (2013) reviewed seven RCTs that compared cannabinoids (dronabinol 
and nabilone) with a placebo. These included four parallel group and three crossover 
trials, all with small sample sizes and short durations of treatment (21 to 84 days). 
Only three clearly randomised patients to treatment. Outcomes that were assessed 
included weight gain and self-reported appetite. The authors assessed the evidence 
as very weak and noted that all the studies had been done before effective 
antiretroviral treatment was introduced for AIDS. 
Intractable epilepsy 
Gloss, D. and Vickrey, B. (2014), ‘Cannabinoids for epilepsy’, Cochrane Database of 
Systematic Reviews 3, CD009270. 
Gloss and Vickrey (2014) reviewed four RCTs that compared the effects of adding a 
cannabinoid or placebo to conventional anti-epileptic drugs in treatment-resistant 
epilepsy. These trials included 48 patients and all evaluated the effects of adding 
CBD to an anti-convulsant, which was continued in all the studies. The primary 
outcome measured was freedom from seizures. All the studies were judged to be of 
low quality. The authors concluded that no reliable conclusions could be drawn about 
the efficacy and safety of CBD in intractable epilepsy. 
 
Stockings, E., Zagic, D., Campbell, G., Weier, M., Hall, W. D., Nielsen, S. et al. 
(2018b), ‘Evidence for cannabis and cannabinoids for epilepsy: a systematic review 
of controlled and observational evidence’, Journal of Neurology, Neurosurgery, and 
Psychiatry 89, pp. 741-753. 
Stockings et al. (2018b) reviewed 6 clinical trials (involving 555 patients) and 30 
observational studies (involving 2 865 patients) that evaluated CBD in intractable 
epilepsy (primarily in children). All participants, whose average age was 13 years, 
had a rare form of epilepsy that had not responded to treatment with other anti-
epileptic drugs. A pooled analysis showed that CBD was more effective than placebo 
in reducing seizure frequency by 50 % or more and in improving quality of life. Eight 
patients needed to receive CBD for one to reduce their seizure frequency by 50 % or 
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more. CBD was also more effective than placebo at completely controlling seizures, 
but this was a very rare outcome. 
The risk of side effects (dizziness and drowsiness), was 24 % higher for CBD than 
placebo. Serious side effects occurred at twice the rate in those taking CBD 
compared with those given a placebo. Pooled data from the 17 observational studies 
indicated that seizure frequency decreased by 50 % or more in just under half of the 
patients and disappeared in 8.5 %. Quality of life improved for half of the patients in 
12 of the observational studies. 
 
Palliative care for cancer 
Mucke, M., Weier, M., Carter, C., Copeland, J., Degenhardt, L., Cuhls, H. et al. 
(2018b), ‘Systematic review and meta-analysis of cannabinoids in palliative 
medicine’, Journal of Cachexia, Sarcopenia, and Muscle 9, pp. 220-234. 
Mucke et al. (2018b) reported a systematic review and meta-analysis of studies of 
the efficacy, tolerability and safety of cannabinoids in palliative medicine for cancer 
and AIDS. They found nine studies with 1 561 participants, all of which were judged 
to have a moderate risk of bias. The quality of evidence comparing cannabinoids 
with placebo was rated as low or very low because of imprecision and potential 
reporting bias. In cancer patients, there were no significant differences between 
cannabinoids and placebo in improving caloric intake (standardised mean difference 
(SMD): 0.2 (95 % CI −0.66 to 1.06)), appetite (SMD: 0.81 (95 % CI −1.14 to 2.75)) or 
nausea/vomiting (SMD: 0.21 (95 % CI −0.10 to 0.52)), or in achieving a greater than 
30 % decrease in pain severity (risk difference (RD): 0.07 (95 % CI −0.01 to 0.16)) or 
improving sleep problems (SMD: −0.09 (95 % CI −0.62 to 0.43)). In the case of HIV 
patients, the authors found that cannabinoids were superior to placebo for weight 
gain (SMD: 0.57 (95 % CI 0.22 to 0.92) and improving appetite (SMD: 0.57 (95 % CI 
0.11 to 1.03)) but not for reducing nausea/vomiting (SMD: 0.20 (95 % CI −0.15 to 
0.54); p = 0.26). In cancer patients, they found no differences between cannabinoids 
and placebo in relation to dizziness (RD: 0.03 (95 % CI −0.02 to 0.08)) or poor 
mental health (RD: −0.01 (95 % CI −0.04 to 0.03)). In HIV patients, there was an 
increase in mental health symptoms in those given cannabinoids (RD: 0.05 (95 % CI 
0.00 to 0.11)). The number of patients who withdrew from treatment because of 
adverse events did not differ significantly between cannabinoid and placebo in 
cancer patients (RD: 1.15 (95 % CI 0.80 to 1.66)) or HIV patients (RD: 1.87 (95 % CI 
0.60 to 5.84)). 
There was a high degree of uncertainty about patient safety because of the small 
sample sizes in many of the studies. The authors ‘found no convincing, unbiased, 
high quality evidence suggesting that cannabinoids are of value for anorexia or 
cachexia in cancer or HIV patients’. They also ‘did not find any significant differences 
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between cannabinoids and placebo in improving caloric intake, appetite, nausea or 
vomiting, pain, or sleep in terminally ill cancer patients’. Their confidence in their 
conclusions was limited by the small number of high-quality studies in the review and 
the small sample sizes of the studies, both of which reduced the chances of finding 
any differences between cannabinoids and placebo. Larger, better-designed trials 
are needed to assess the value of cannabis and cannabinoids in palliative cancer 
care. 
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3. Adverse effects of the medical use of cannabis and 
cannabinoids 
 
Short-term risks 
The short-term effects of medical use of cannabinoids and cannabis have been 
studied in a substantial number of randomised controlled clinical trials in a diverse 
range of medical conditions, typically for periods of 8 to 12 weeks. The trial length 
has varied with condition: trials looking at nausea and vomiting due to chemotherapy 
lasted from 1 to 6 days, while trials looking at conditions such as appetite, pain or 
spasticity associated with MS lasted from 8 to 15 weeks (Whiting et al., 2015). 
Wang et al. (2008) conducted a meta-analytic review of adverse effects reported in 
RCTs of cannabinoids and cannabis extracts for various medical uses. They also 
considered case reports of adverse events among cannabis users and observational 
studies of adverse events among recreational cannabis users. Most adverse events 
(97 %) reported in the clinical trials were very minor, with dizziness (20 %) being the 
most common. The authors did not find any elevated risk of serious adverse events 
in patients using cannabinoid drugs (either plant extracts or THC preparations) 
compared with placebo (Wang et al., 2008). 
These findings supported the conclusion reached in a 1999 report (Institute of 
Medicine, 1999) that the short-term use of cannabinoids for medical purposes had 
an acceptable profile of adverse effects. The review was unable to provide 
information on the longer term use of cannabinoids for chronic disorders, such as 
MS, because the available trials had been relatively short term (8 hours to 12 
months) (Wang et al., 2008). 
Whiting et al. (2015) reported a meta-analysis on the adverse events reported in 79 
trials that evaluated the medical use of cannabinoids for nausea and vomiting, 
appetite stimulation, chronic pain, spasticity due to MS, depression, anxiety, sleep 
disorder, psychosis, glaucoma or movement disorder due to Tourette syndrome. 
Table 4 summarises the prevalence of any adverse effects, serious adverse effects 
and withdrawal from studies. It also indicates the number of studies and the number 
of patients on which the estimates are based and uses the odds ratio to express the 
difference in the likelihood of these events between patients receiving a cannabinoid 
and those receiving a placebo. 
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Table 4: Prevalence of any adverse effects, serious adverse effects and withdrawal 
(based on Whiting et al., 2015) 
 Studies (n) Patients 
(n) 
OR 
Any adverse effects 29 3 714 3.03 
Serious adverse effects 34 3 248 1.41 
Withdrawal 23 2 755 2.94 
 
Adverse events were more common among patients who received a cannabinoid 
than among those who received a placebo. So were serious adverse events, 
although the difference in odds was smaller. Patients who received a cannabinoid 
were also more likely to withdraw from the study. 
Table 5 shows the most commonly reported adverse effects and the number of 
studies and patients in whom they were reported. The adverse effects reported most 
often by patients who received cannabinoids were dizziness, dry mouth, nausea, 
fatigue, somnolence and euphoria. 
 
Table 5: Most commonly reported adverse effects (based on Whiting et al., 2015) 
 Studies (n) Patients (n) OR 
Dizziness 41 4 243 5.09 
Dry mouth 36 4 181 3.50 
Nausea 30 3 579 2.08 
Fatigue 20 2 717 2.00 
Somnolence 26 3 168 2.83 
Euphoria 27 2 420 4.08 
Depression 15 2 353 1.32 
Vomiting 17 2 191 1.67 
Diarrhoea 17 2 077 1.65 
Disorientation 12 1 736 5.41 
Asthenia 15 1 717 2.03 
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Information is lacking in many reviews on possible interactions between 
cannabinoids and other drugs (Martin and Bonomo, 2016). This is an important 
evidence gap because cannabinoids are most often used as adjunctive treatments in 
combination with other drugs, such as opioids and other analgesics in the case of 
chronic pain, immunosuppressant drugs in the case of MS and anti-epileptic drugs in 
the case of intractable epilepsy. 
Long-term risks 
There is very little evidence on the longer term adverse effects reported by patients 
who use cannabis-based medicines regularly over months or years. One study by 
Serpell et al. (2013) reported the adverse events experienced by patients taking part 
in an open-label trial of Sativex for spasticity due to MS. Patients who had previously 
taken part in a 6-week RCT of Sativex were invited to continue to receive the drug in 
an open-label extension trial for up to 3 years. Eighty-four per cent (n = 145) of the 
patients who finished the RCT continued in the open-label trial; 35 patients used 
Sativex for up to 1 year, 43 patients used it for up to 2 years, and 4 patients used it 
for up to 3 years. Ninety-five per cent of patients experienced an adverse event, but 
the majority of these were mild to moderate in severity. The most common involved 
dizziness, fatigue or headache. A total of 23 patients (16 %) withdrew from the study 
due to adverse events. 
Two observational studies have reported on adverse effects in cancer patients (Bar-
Lev Schleider et al., 2018) and elderly patients (Abuhasira et al., 2018) treated in a 
leading Israeli cancer hospital between January 2015 and October 2017. Adverse 
events were assessed in a telephone interview conducted 6 months after treatment 
started. Among cancer patients, 31 % reported an adverse event; these most 
commonly related to dizziness (8.0 %), dry mouth (7.3 %), increased appetite 
(3.6%), sleepiness (3.3 %) and psychoactive effects (2.8 %) (Bar-Lev Schleider et 
al., 2018). The prevalence and type of adverse events were very similar in older 
patients treated with cannabis for more varied medical conditions (Abuhasira et al., 
2018). 
There have not yet been any studies of adverse events associated with the regular 
use of CBD in children treated for intractable epilepsy. This should be a research 
priority given concerns about the possible effects of long-term medication use on 
brain development in children and adolescents. 
Risks associated with long-term recreational cannabis use 
In the light of the sparse evidence on the long-term harms that may be associated 
with medical use, a number of reviews have reviewed evidence of harms from long-
term recreational use to identify possible harms that should be monitored in medical 
treatment using cannabinoids (see, for example, Wang et al., 2008). Observational 
population-based cohort studies of recreational cannabis users may provide an 
indication of possible adverse effects of long-term cannabis use. There are major 
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uncertainties, however, about the extent to which these risks apply to the use of 
cannabinoid medicines. Cannabis preparations for medical purposes are typically 
used in lower doses by older adults using an oral route, whereas recreational users 
are generally younger adults who smoke potent cannabis products, often daily. 
Respiratory diseases 
Long-term cannabis smoking is associated with the development of chronic 
bronchitis (Hall et al., 2016; NASEM, 2017). There have been more mixed reports on 
the risk of chronic obstructive pulmonary disease (Hall et al., 2016; NASEM, 2017). 
The potential respiratory risks primarily arise because cannabis is smoked in a 
combustible cigarette and, in many instances, combined with tobacco (Tan et al., 
2009). If the patient consumes the cannabinoid orally in the form of a capsule or in 
an oil, then respiratory risks will not arise. The use of vaporisers would probably also 
reduce this risk, but it is unclear by how much. 
Cognitive impairment 
Long-term heavy use of cannabis for recreational purposes has also been 
associated with poorer cognitive function — specifically memory, attention, decision-
making and planning (Crean et al., 2011; Solowij et al., 2002). This risk may be a 
concern for patients who are using cannabinoids over the long term and wish to 
continue activities in which reduced cognitive performance may be an issue. 
Psychiatric disorders 
Longitudinal and cohort studies have indicated that long-term or heavy cannabis use 
is associated with a greater prevalence of symptoms of depression (Degenhardt et 
al., 2003), mania (Henquet et al., 2006) and psychosis (van Os et al., 2002). Long-
term regular cannabis use is associated with the development of depression, 
anxiety, mania and hypomania in individuals with bipolar disorder, suicidal thoughts 
and suicide completion, social anxiety, and PTSD symptoms (NASEM, 2017) (see 
Table 5). Debate continues about which of these associations are causal. There is 
limited evidence from prospective cohort studies for most of these disorders, so it is 
difficult to exclude the possibility that cannabis is used to self-medicate symptoms of 
the disorders. 
There is support for a causal relationship in the case of psychosis (Hall et al., 2016; 
NASEM, 2017). Prospective studies suggest that long term daily cannabis use may 
precipitate psychotic symptoms or disorders in young people who are vulnerable 
because of personal or family history (Degenhardt and Hall, 2006; NASEM, 2017). 
Again, this evidence is derived from people who have used cannabis for recreational 
purposes, typically daily from their mid-teens and into young adulthood. It remains 
uncertain whether the same risks would arise from daily use of a synthetic 
cannabinoid or cannabis preparation that was consumed in controlled doses by an 
older patient. Nevertheless, people who have a personal or family history of 
psychosis might be wise to avoid using cannabis for any reason (Degenhardt and 
Hall, 2006; Hall et al., 2016). 
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Cannabis dependence 
One possible consequence of long-term medical use of cannabis is the risk of 
developing cannabis dependence. The risk is highest (Hall, 2015; Hall et al., 2001) 
among recreational cannabis users who began using in adolescence and early 
adulthood, and who used the most potent cannabis products. These users have 
probably smoked cannabis with a greater frequency and intensity than would older 
adults using smaller doses for symptom relief (Hall et al., 2016). We know nothing of 
the incidence of cannabis dependence in long-term, medically supervised medical 
use, such as that which might occur if cannabis were used to treat chronic pain. 
Here, the risk of dependence could plausibly be considered higher than in more 
episodic medical use, such as for chemotherapy-induced nausea, although it is 
unclear by how much. 
Cardiovascular risk 
The cardiovascular disease risk posed by cannabis and cannabinoids is a concern in 
relation to medical use of cannabis because the risk of these diseases is higher in 
the older populations that are likely to use cannabis for medical reasons (Hall and 
Degenhardt, 2003). One epidemiological study found that heavy cannabis users 
(who were also heavy tobacco and alcohol users and had other elevated risk factors 
for adverse outcomes) were at slightly elevated risk of mortality at later follow-up, but 
their deaths were not related to cardiovascular causes (Mukamal et al., 2008). More 
recent reviews have suggested that cannabis use, both short term and long term, 
increases the risk of triggering a myocardial infarction (Franz and Frishman, 2016; 
Hall et al., 2016; NASEM, 2017) and may also do so for stroke (Hall et al., 2016). 
Cancers 
The cancer risks posed by cannabis smoking remain uncertain. There have been 
inconsistent findings in epidemiological studies: some have suggested no increased 
cancer risk, and some case-control studies have suggested some elevation of risk in 
very heavy long-term smokers (Aldington et al., 2008; Hashibe et al., 2006). Some 
evidence suggests that long-term recreational use may be associated with an 
increased risk of developing testicular, prostate or ovarian cancer (Hall et al., 2016). 
However, these associations are most pertinent to cannabis smoking and probably 
less of an issue for oral use of cannabis oils or cannabinoids. 
Summary 
Based on the current data, the risk of adverse effects from the short-term use of 
medical cannabinoids and cannabis extracts is greater than that from placebo, but 
the most common adverse events are minor, for example involving dizziness or 
somnolence, and serious adverse events are rare. The risk may be marginally 
greater for oral THC than for combinations of CBD and THC or for cannabis extract 
preparations (Wang et al., 2008). CBD may counteract some of the adverse effects 
of THC (Zuardi et al., 2006). We need better information on the adverse effects of 
more sustained use of cannabinoids and cannabis preparations from follow-up 
studies of patients using these preparations for chronic pain and epilepsy, so that we 
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can assess the risks of cannabis dependence and cardiovascular disease in medical 
cannabis users. 
  
32 
 
4. Focus on the US — potential unintended consequences of the 
medical use of cannabis and cannabinoids 
 
When considering the outcomes of regulatory changes to allow access to cannabis 
and cannabinoids for medical use, in addition to considering health risks and benefits 
for patients it is important to consider potential broader social and public health 
impacts. There are now a growing number of studies, primarily from the US, 
investigating these wider impacts. However, as with the evidence concerning the 
clinical effectiveness of different cannabis products and preparations, variations in 
approaches, definitions and data sources makes drawing firm conclusions difficult, 
with studies often having contradictory outcomes or inconclusive results. 
In this section, a few issues considered in medical cannabis studies to date are 
discussed to illustrate the types of potential unintended consequences, both positive 
and negative, that may need to be considered when making cannabis or 
cannabinoids available for medical use. 
 
The impact of medical use of cannabis on recreational cannabis use and 
cannabis disorders 
One of the possible issues is the impact of medical use of cannabis on recreational 
cannabis use. Data from US household surveys suggest that cannabis use may 
have increased among adults over the age of 21 years between 2004 and 2012 after 
laws on the medical use of cannabis were passed (Wen et al., 2015). There were no 
differences in rates of new adult cannabis users between states with laws on the 
medical use of cannabis and states without such laws, but adults in states with laws 
on the medical use of cannabis were more likely to report higher rates of cannabis 
use in the past 30 days (an increase of 1.3 %), higher rates of daily cannabis use (an 
increase of 0.6 %) and higher rates of cannabis abuse/dependence (an increase of 
10 %) than adults who lived in states that had not passed laws on the medical use of 
cannabis. 
There are conflicting findings on whether cannabis dependence has increased 
overall in the US adult population over the two decades in which laws on the medical 
use of cannabis have been enacted. The National Epidemiologic Survey of Alcohol 
and Related Conditions concluded that the prevalence of cannabis use disorders 
increased between 1991-1992 and 2001-2002 (Compton et al., 2004) but that rates 
of cannabis use remained stable. The prevalence of cannabis use disorders 
increased again between 2001-2002 and 2012-2013, and so did the prevalence of 
cannabis use (Hasin et al., 2015). 
These studies were not supported by Compton et al.’s 2016 analysis of trends in 
cannabis use in US adults aged 18 years and older in annual surveys between 2002 
and 2014 (Compton et al., 2016). The prevalence of past year cannabis use 
increased from 10 % in 2002 to 13 % in 2014, with rates increasing most steeply 
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after 2007. Rates of initiation of cannabis use in the past 12 months increased from 
0.7 % to 1.1 % and the prevalence of daily or near daily cannabis use increased from 
1.9 % to 3.5 %, again beginning in 2007. 
Surprisingly, despite the increased prevalence of adult cannabis use, the prevalence 
of cannabis use disorders in the past year remained at 1.5 % in adults across this 
period. More surprisingly, the risk of disorders declined among adults who had used 
cannabis in the past year from 15 % in 2002 to 11.0 % in 2014. This finding is 
surprising because one might expect an increase in these disorders among users 
when the prevalence and frequency of cannabis use and the use of more potent 
cannabis products increase (Freeman and Winstock, 2015; Mehmedic et al., 2010). 
There are a number of possible explanations for the decreased prevalence of 
cannabis use disorders found in Compton et al.’s 2016 study despite the increase in 
the prevalence of near daily cannabis use. First, there could be an age cohort effect. 
Grucza et al. (2016) found a decline in use among 12- to 17-year-olds, who are at a 
higher risk of developing cannabis use disorder. Compton et al. (2016) found 
increased use in those over the age of 18 years. Younger users are more likely to 
develop dependence, whereas older users may be more likely to use cannabis 
without developing dependence. A second possibility is that liberalisation of cannabis 
policy has increased the number of cannabis users among older adults, possibly by 
increasing the number of former users who resume cannabis use. Older adults 
generally use less often, and so the proportion of current users who meet criteria for 
cannabis use disorders could have been reduced. 
One study has examined the effects of laws on the medical use of cannabis on 
treatment seeking for cannabis use disorders. Choo et al. (2014) compared the 
number of people seeking first-time treatment for cannabis problems between 1992 
and 2011 in states that did and did not have these laws. They found a 15-21 % 
increase in new treatment episodes for primary cannabis use problems in people 
who had not been referred by the criminal justice system after laws on the medical 
use of cannabis were passed. 
 
The impact of medical use of cannabis on use among young people 
An additional concern has been that these laws will increase adolescent cannabis 
use by making cannabis more available to young people and sending the unintended 
message that cannabis use is not risky. Researchers have evaluated these concerns 
using survey data to compare trends in cannabis use in adolescents in states that 
have and have not legalised medical cannabis use. These surveys were not primarily 
designed for this task. They were designed to provide representative samples of the 
US high school population nationally, as opposed to profiling the high school 
populations of individual states. In order to compare populations in states that have 
legalised and not legalised medical marijuana, data often have to be averaged over 
two survey years to produce stable estimates. 
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Comparisons of adolescent cannabis use in household and school-based surveys 
have generally not found differences in use between states with and without medical 
marijuana laws (MMLs) (see, for example, Ammerman et al., 2015; Cerda et al., 
2012; Choo et al., 2014; Harper et al., 2012; Lynne-Landsman et al., 2013; 
Schuermeyer et al., 2014; Wall et al., 2011; Wall et al., 2012). 
The largest study of adolescent cannabis use in the US to date was based on 
national surveys of secondary school students funded by the National Institute on 
Drug Abuse. Using data from Monitoring the Future Surveys run between 1991 and 
2014, Hasin et al. (2015) compared trends in past 30 day cannabis use in the 21 
states that had legalised medical marijuana use with those in the 27 mainland US 
states that had not, while controlling for social, economic and demographic 
differences between states and schools. Hasin et al. found that states that had 
passed MMLs had higher rates of past 30 day cannabis use before the laws were 
passed (16 % vs. 13 %) than states that had not. There was no change in 
adolescent cannabis use before and after the passage of MMLs (16.3 % pre to 
15.5 % post). Indeed, there was a reduction in rates of cannabis use in eighth grade 
students in states with MMLs. 
Comparisons of trends in cannabis use among young people aged 12 to 20 years in 
the US National Survey on Drug Use and Health show similar results (Wen et al., 
2015). The proportion of young people in MML states who reported using cannabis 
in the year after the MMLs were passed marginally increased between 2004 and 
2012, but there was no increase in cannabis use in the past 30 days and no increase 
in daily use. 
 
The medical use of cannabis and cannabis-related motor vehicle 
fatalities 
Studies evaluating the effects of MMLs on cannabis-related motor vehicle fatalities 
have produced mixed results. Some (Masten and Guenzburger, 2014) have found 
an increase in the percentage of cannabis-impaired drivers detected in fatal crashes 
in states that have passed MMLs. The complication is that testing drivers for 
cannabis use became more common after MMLs were enacted. 
Anderson et al. (2013) examined the role of alcohol in car crashes between 1990 
and 2010 in US states that did and did not have MMLs. They found an 8-11 % 
greater decrease in total traffic fatalities and in fatalities with a blood alcohol 
concentration greater than 0.08 % in states with MMLs. They argued that this effect 
was the result of young males substituting cannabis for alcohol because cannabis 
was cheaper in MML states. They cited as supporting evidence that there were 
larger reductions in alcohol consumption and beer sales in states that had passed 
MMLs. 
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A comparison of trends in fatal motor vehicle crashes in Colorado and 34 states 
without MMLs between 1994 and 2011 produced inconsistent results (Salomonsen-
Sautel et al., 2014). The authors found a larger increase in cannabis-positive 
fatalities in Colorado after 2009 than in the 34 states without MMLs. They also found 
no change in alcohol-related motor vehicle fatalities in Colorado or the 34 states 
without MMLs. 
 
Medical use of cannabis and suicides 
Anderson et al. (2014) reported steeper declines in suicides among males aged 20 
to 30 years in US states that had legalised medical marijuana than in those that had 
not. An analysis that controlled for differences between states did not support their 
finding (Grucza et al., 2015). Rylander et al. (2014) did not find any association 
between suicide rates and the number of medical marijuana patients in US states 
between 2004 and 2010. 
 
Medical use of cannabis and other substances 
A number of studies of MMLs have examined trends in alcohol-related harm to see if 
young men may be using cannabis as a substitute for alcohol in states with MMLs 
(Anderson et al., 2014). Wen et al.’s 2015 analysis of National Survey on Drug Use 
and Health data did not find a greater reduction in alcohol use among people under 
the age of 21 years in states with MMLs. Indeed, they found more binge drinking, 
and more concurrent use of alcohol and cannabis, among adults aged over 21 years 
in states with MMLs. 
An analysis of opioid overdose deaths in the US found lower rates of these deaths in 
states with MMLs than in those without such laws, and the difference in overdose 
death rates increased over time (Bachhuber et al., 2014). This finding has been 
interpreted as evidence that the substitution of cannabis for opioids in pain relief has 
reduced the number of fatal opioid overdoses. However, a correlation between time 
series data on opioid overdose deaths and state MMLs is weak evidence for a 
causal relationship (Finney et al., 2015). Better evidence is needed, namely that 
cannabis and opioid use have changed in the ways required for a causal 
relationship, and that the association is not explained by other policy differences 
(e.g. rates of imprisonment of opioid users and provision of methadone-assisted 
treatment) between states that have and have not passed MMLs (Hall et al., 2018; 
Hayes and Brown, 2014). 
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